BidaskClub upgraded shares of Natus Medical (NASDAQ:BABY) from a hold rating to a buy rating in a research report released on Tuesday morning.
A number of other research analysts have also weighed in on BABY. Roth Capital set a $39.00 target price on Natus Medical and gave the stock a buy rating in a report on Tuesday, February 27th. Zacks Investment Research raised Natus Medical from a strong sell rating to a hold rating in a report on Tuesday, April 10th. Finally, ValuEngine lowered Natus Medical from a hold rating to a sell rating in a report on Thursday, May 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. Natus Medical currently has an average rating of Hold and an average target price of $44.33.
Shares of Natus Medical opened at $36.30 on Tuesday, Marketbeat reports. Natus Medical has a 12-month low of $28.00 and a 12-month high of $43.60. The company has a market cap of $1.21 billion, a PE ratio of 25.96 and a beta of 0.49. The company has a current ratio of 3.06, a quick ratio of 2.28 and a debt-to-equity ratio of 0.31.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings data on Wednesday, April 25th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.24. Natus Medical had a positive return on equity of 10.96% and a negative net margin of 4.71%. The company had revenue of $128.60 million for the quarter, compared to analysts’ expectations of $125.91 million. During the same quarter in the prior year, the business posted $0.30 EPS. The business’s revenue was up 3.1% compared to the same quarter last year. equities analysts expect that Natus Medical will post 1.62 earnings per share for the current fiscal year.
Natus Medical declared that its board has authorized a share repurchase program on Thursday, February 22nd that allows the company to buyback $30.00 million in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.
In other Natus Medical news, Director William M. Moore sold 8,000 shares of the company’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $35.91, for a total value of $287,280.00. Following the transaction, the director now directly owns 30,410 shares of the company’s stock, valued at approximately $1,092,023.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider James B. Hawkins sold 160,000 shares of the company’s stock in a transaction on Monday, April 30th. The shares were sold at an average price of $33.47, for a total value of $5,355,200.00. Following the completion of the transaction, the insider now directly owns 686,757 shares in the company, valued at $22,985,756.79. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 183,358 shares of company stock worth $6,154,209. Insiders own 5.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of BABY. Teacher Retirement System of Texas acquired a new position in Natus Medical in the 4th quarter valued at $433,000. Swiss National Bank grew its holdings in Natus Medical by 4.4% in the 4th quarter. Swiss National Bank now owns 56,500 shares of the medical equipment provider’s stock valued at $2,158,000 after buying an additional 2,400 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Natus Medical by 45.9% in the 4th quarter. Wells Fargo & Company MN now owns 145,534 shares of the medical equipment provider’s stock valued at $5,558,000 after buying an additional 45,793 shares in the last quarter. Advisory Services Network LLC grew its holdings in Natus Medical by 5,890.3% in the 4th quarter. Advisory Services Network LLC now owns 14,856 shares of the medical equipment provider’s stock valued at $567,000 after buying an additional 14,608 shares in the last quarter. Finally, Pinebridge Investments L.P. grew its holdings in Natus Medical by 267.1% in the 4th quarter. Pinebridge Investments L.P. now owns 15,103 shares of the medical equipment provider’s stock valued at $577,000 after buying an additional 10,989 shares in the last quarter. 89.20% of the stock is currently owned by hedge funds and other institutional investors.
About Natus Medical
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.